
==== Front
J Cancer Res Clin Oncol
J Cancer Res Clin Oncol
Journal of Cancer Research and Clinical Oncology
0171-5216
1432-1335
Springer Berlin Heidelberg Berlin/Heidelberg

39264423
5933
10.1007/s00432-024-05933-w
Research
RAC1 serves as a prognostic factor and correlated with immune infiltration in liver hepatocellular carcinoma
Li Yuan 1
Gu Aidong 2
Yang Lili 1
Wang Qingbo luoriwangchao@126.com

1
1 https://ror.org/04523zj19 grid.410745.3 0000 0004 1765 1045 Department of Chemotherapy, The Second Hospital of Nanjing，Affiliated to Nanjing University of Chinese Medicine, Nanjing, China
2 https://ror.org/04523zj19 grid.410745.3 0000 0004 1765 1045 Department of Hepatobiliary Surgery, The Second Hospital of Nanjing，Affiliated to Nanjing University of Chinese Medicine, Nanjing, China
12 9 2024
12 9 2024
2024
150 9 41820 6 2024
28 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Background

Hepatocellular carcinoma (LIHC) has severe consequences due to late diagnosis and the lack of effective therapies. Currently, potential biomarkers for the diagnosis and prognosis of LIHC have not been systematically evaluated. Previous studies have reported that RAC1 is associated with the B cell receptor signaling pathway in various tumor microenvironments, but its relationship with LIHC remains unclear. We investigated the relationship between RAC1 and the prognosis and immune infiltration microenvironment of LIHC, exploring its potential as a prognostic biomarker for this type of cancer.

Methods

In this study, we analyzed data from The Cancer Genome Atlas (TCGA) using the Wilcoxon signed-rank test and logistic regression to assess the association between RAC1 expression and clinical characteristics in LIHC patients. Additionally, Kaplan-Meier and Cox regression methods were employed to confirm the impact of RAC1 expression levels on overall survival. Immunohistochemistry was used to validate RAC1 protein expression in LIHC. We constructed RAC1 knockdown LIHC cells and studied the effects of RAC1 protein on cell proliferation and migration at both cellular and animal levels.

Results

RAC1 expression levels were significantly elevated in LIHC tissues compared to normal tissues. High RAC1 expression was strongly associated with advanced pathological stages and was identified as an independent factor negatively affecting overall survival. At both cellular and animal levels, RAC1 knockdown significantly inhibited the proliferation and migration of LIHC cells. Furthermore, RAC1 expression was positively correlated with the infiltration of Th2 cells and macrophages in the tumor microenvironment, suggesting that RAC1 may contribute to the deterioration of the tumor immunosuppressive microenvironment and potentially lead to reduced patient survival.

Conclusion

These findings indicate that RAC1 expression promotes LIHC proliferation and migration and influences the landscape of immune cell infiltration in the tumor microenvironment. Based on these results, RAC1 is proposed as a potential prognostic biomarker for LIHC, associated with both cancer progression and tumor immune cell infiltration.

Supplementary Information

The online version contains supplementary material available at 10.1007/s00432-024-05933-w.

Keywords

RAC1
Liver hepatocellular carcinoma
Overall survival
Immune infiltration
National Natural Science Foundation of China81800197 issue-copyright-statement© Springer-Verlag GmbH Germany, part of Springer Nature 2024
==== Body
pmcIntroduction

The Rho family of GTPases, a subfamily of the Ras superfamily, consists of small (~ 21 kD) signaling G proteins. These GTPases typically switch between active and inactive states by exchanging guanosine diphosphate (GDP) and guanosine triphosphate (GTP) molecules(Jin et al. 2024), reliably binding to specific proteins and activating signaling cascades. Among them, RAC1 plays a crucial role in regulating cell growth, angiogenesis, tissue remodeling, and cell migration(Tátrai et al. 2024). In the unstimulated state, RAC1 exists in the cytosol as a complex with guanine nucleotide dissociation inhibitors (GDIs). Upon activation by soluble chemoattractant, chemokines, phagocytic particles, or any upstream regulators, RAC1 initiates signaling. This activation involves the dissociation of RAC1 from GDIs and the exchange of GDP for GTP facilitated by membrane-localized guanine nucleotide exchange factors. Consequently, RAC1, in its GTP-bound form, becomes anchored to the membrane(Yamauchi et al. 2005; Alvarez and Agaisse 2014).

Furthermore, RAC1 is associated with tumor progression and tumor immune microenvironment(Shi et al. 2024). Immune cell infiltration is a major component of the tumor microenvironment, and the activation or inactivation of RAC1 within this environment not only affects the plasticity of tumor cell movement but may also influence immune cell infiltration by regulating various signaling pathways, thereby impacting the overall landscape of the tumor microenvironment(Sanz-Moreno et al. 2008; De et al. 2019). Therefore, a better understanding of the relationship between RAC1 gene expression and immune cell infiltration within the tumor microenvironment is essential for deciphering immunotherapeutic mechanisms, defining predictive biomarkers, and identifying new therapeutic targets(Zhou et al. 2021; Sauzeau et al. 2022b).

Previous studies have shown that RAC1 gene expression is higher in melanoma, glioblastoma, colon cancer and ovarian cancer compared to adjacent normal tissues(Hudson et al. 2018; Al-Koussa et al. 2020; Kotelevets and Chastre 2020; Cannon et al. 2020). Unfortunately, the crucial role of RAC1 in the development and progression of liver hepatocellular carcinoma (LIHC) remains largely uncharacterized. Our study aims to discover whether RAC1 genes expression level is a potential diagnostic and prognostic marker and its association with immune infiltration in LIHC.

Materials and methods

Dataset source and preprocessing

The expression levels of RAC1 in 424 LIHC samples with 50 adjacent normal tissue samples were analyzed based on the dataset of The Cancer Genome Atlas (TCGA-LIHC) mRNA sequencing (RNA-seq) database. Clinical characteristics such as tumor statue, histologic grades, pathologic stages and vascular invasion were assessed with respect to their respective clinical patterns. Differential transcriptional expression was compared to Student`s t-test.

Immune infiltration algorithm

Based on the ssGSEA algorithm provided in R-packet-GSVA [1.46.0], the provided markers of 24 immune cells were used to calculate the immune infiltration of the corresponding data.

Diagnostic analysis

The Receiver Operating Characteristic (ROC) curve was applied to assess the specificity and sensitivity of gene prediction accuracy, using the area under the ROC curve (AUC) as a diagnostic value based on the “pROC” package in the statistical software (version 1.18.0) was used.

Survival analysis

The Kaplan-Meier curve was performed to compare overall survival (OS) between the differential expression groups of RAC1 including 424 LIHC samples in the TCGA database and KM Plotter, respectively. The correlation between RAC1 expression and survival was analyzed to discover the significant prognostic factors. The hazard ratio (HR) with 95% confidence interval (CI) and log-rank P value were also calculated.

Correlation analysis

Gene expression correlation analysis was performed for given sets of mRNA expression data in TCGA-LIHC were used for analysis. The correlation coefficient was determined by the Spearman method.

Immunohistochemical staining (IHC)

We have obtained the IHC result of hepatocellular carcinoma sample (ID: 2766) from The Human Protein Atlas (https://www.proteinatlas.org/). Meanwhile, we also explored the RAC1 protein level in LIHC by IHC using a commercial tissue microarray (Bioaitech Co., Xi’an, China, cat #D202Lv01) with 10 LIHC and 10 normal liver tissues. IHC procedure was conducted as follows: tissues were first dewaxed and hydrated, followed by antigen retrieval and blocking of endogenous peroxidase activity. The slides were then incubated with the primary antibody overnight at 4 °C. After incubation with the secondary antibody, the slides were stained with diaminobenzidine (DAB). For the evaluation and scoring, two pathologists independently assessed the staining results. RAC1 protein expression was scored based on both the percentage of positively stained tumor cells and the staining intensity. Specifically, the percentage of immunoreactive tumor cells was scored as 1 (< 10%), 2 (10–25%), 3 (26–49%), and 4 (≥ 50%). Staining intensity was visually assessed and scored as 1 (negative), 2 (light yellow), 3 (light brown), and 4 (dark brown). The final immunoreactivity score for each case was obtained by multiplying the percentage score by the intensity score.

Cell culture

The LIHC cell lines utilized in this study, HepG2 and Huh7, were procured from the China Center for Type Culture Collection. The complete culture medium formulation used for cell culture consisted of Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin. The cells were cultured in an incubator maintained at 37 °C with 5% CO2. Cells in the logarithmic growth phase were used for subsequent experiments.

Transfection of small interfering RNA

The siRNAs used in this study were sourced from Genscript Co., Ltd., located in Nanjing, China. For the transfection of siRNAs into liver hepatocellular carcinoma (LIHC) cell lines, we utilized Lipofectamine 2000 (Invitrogen, Carlsbad, USA), following the manufacturer’s instructions.

The transfection procedure began with seeding LIHC cells onto cell culture plates. The cells were cultured in appropriate growth medium until they reached approximately 50% confluence. At this stage, the siRNAs were prepared for transfection. Each siRNA was diluted in an opti-MEM medium and mixed with Lipofectamine 2000 reagent in a separate tube. The siRNA-Lipofectamine 2000 mixture was then incubated at room temperature for 20 min to allow for the formation of siRNA-lipid complexes.

Following incubation, the siRNA-lipid complex was added to the cells in their culture plates. The final concentration of siRNA in the transfection mixture was set to 100 nM. The cells were then incubated with this transfection mixture for 48 h to ensure sufficient uptake and effective gene silencing.

The siRNAs used in this study had the following sequences:

siRAC1-1: 5’-AAGACAAGCCGATTGCCGACG-3’.

siRAC1-2: 5’-AAGCCGATTGCCGACGTGTTC-3’.

Quantitative real-time polymerase chain reaction

The cDNA was amplified using SYBR-Green PCR Master Mix (TAKARA, Tokyo, Japan) on a QuantStudio 5 system (ABI, Carlsbad, USA) under the following conditions: an initial denaturation at 95 °C for 10 min, followed by 40 cycles of denaturation at 95 °C for 15 s and annealing/extension at 60 °C for 1 min. The level of RAC1 mRNA was calculated by 2−ΔΔCt method using GAPDH as internal control.

The sequences of the specific primers used for amplification were as follows:

GAPDH forward, 5’-AGATCCCTCCAAAATCAAGTGG-3’;

GAPDH reverse, 5’- GGCAGAGATGATGACCCTTTT-3’;

RAC1 forward, 5’-ATGTCCGTGCAAAGTGGTATC − 3’;

RAC1 reverse, 5’-CTCGGATCGCTTCGTCAAACA-3’.

Western blotting

After transfecting cells with siRNA for 72 h, cells were collected and lysed using RIPA buffer. Equal amounts of protein from each group were separated by 12% SDS-PAGE and transferred onto PVDF membranes. The membranes were blocked with 5% BSA at room temperature for 1 h, followed by incubation with anti-RAC1 antibody (Abcam, ab155938) and then with HRP-conjugated secondary antibody (Abcam, ab288151). Signal detection was performed using ECL chemiluminescence reagents, and results were recorded with a chemiluminescent imaging system. The membranes were then stripped of antibodies and re-blocked, followed by sequential incubation with anti-GAPDH antibody (Abcam, ab8245) and HRP-conjugated secondary antibody (Abcam, ab205719). ECL detection and imaging were subsequently performed.

Wound healing assay

The migratory ability of different groups of LIHC cells was evaluated using a wound-healing assay. When the cells covered 95% of the bottom of a six-well plate, a 10 µL pipette tip was used to create a straight scratch in the monolayer. The cells were then washed twice with PBS and replenished with complete medium. After imaging, the cells were cultured for an additional 24 h before being imaged again. The migration index was calculated using Image J software with the following formula:

\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\text{M}\text{i}\text{g}\text{r}\text{a}\text{t}\text{i}\text{o}\text{n}\:\text{i}\text{n}\text{d}\text{e}\text{x}=\frac{\left(\text{initial\:scratc}\text{h}\text{\:area\:-\:final\:scratc}\text{h}\text{\:area}\right)}{\text{i}\text{n}\text{i}\text{t}\text{i}\text{a}\text{l}\:\text{s}\text{c}\text{r}\text{a}\text{t}\text{c}\text{h}\:\text{a}\text{r}\text{e}\text{a}}\:$$\end{document}

Proliferation assay

The proliferation capability of different LIHC cell groups was assessed using the CCK-8 assay. When the cells reached 50% confluence, culture medium containing 10% CCK-8 solution was added to each well and incubated at 37 °C for 30 min. Absorbance at 450 nm was then measured for each well. After the measurement, the medium was replaced with fresh culture medium, and cells were cultured further. Proliferation was assessed at various time points, including 1, 2, 4, 8, 12, 24, 36, 48, and 96 h. The proliferation rate of each cell line was calculated relative to the absorbance value at the 0-hour time point.

\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\text{P}\text{r}\text{o}\text{l}\text{i}\text{f}\text{e}\text{r}\text{a}\text{t}\text{i}\text{o}\text{n}\:\text{r}\text{a}\text{t}\text{e}=\frac{{\text{O}\text{D}}_{\text{T}\text{i}\text{m}\text{e}}-{\text{O}\text{D}}_{\text{B}\text{l}\text{a}\text{n}\text{k}}}{{\text{O}\text{D}}_{0\text{h}}-{\text{O}\text{D}}_{\text{B}\text{l}\text{a}\text{n}\text{k}}}$$\end{document}

Subcutaneous tumor xenograft model of LIHC cells

After 72 h of transfection, the cells were collected for tumor xenograft implantation. The LIHC xenograft model was established by subcutaneously injecting different groups of LIHC cells into the right armpits of six-week-old BALB/c nude mice (1 × 10^7 cells per mouse; three animals per group). Tumor size was recorded every other day, and tumor volume was calculated according to the formula: width^2 × length/2. Twelve days after tumor cell implantation, all mice were euthanized, and tumor tissues were collected.

Statistical analysis

The Wilcoxon rank sum test was used to assess the significant differential expression levels of the RAC1 in LIHC with the threshold of gene expression being selected as the median method. Correlation of gene expression was evaluated by Spearman’s correlation coefficient. Univariate Cox analysis was used to screen for potential risk factors, and multivariate Cox analysis was used to verify the independent variate of RAC1 expression on overall survival. All statistical analyzes were performed with the R statistical software (version 4.2.1). A P-value of less than 0.05 is considered statistically significant.

Results

Expression of the RAC1 in LIHC

We analyzed RAC1 mRNA levels in LIHC and adjacent normal tissue samples using TCGA RNA-seq datasets. RAC1 was significantly upregulated in LIHC compared to normal tissues (Fig. 1A and B, Table S1). Immunohistochemical staining further confirmed the elevated RAC1 protein level in LIHC tissues compared to normal liver tissues (Fig. 1C and D).

Fig. 1 Expression of the RAC1 in LIHC (A-B) Evaluation of RAC1 expression in patients with LIHC compared to adjacent normal tissue samples: (A) unpaired samples, (B) paired samples; (C-D) RAC1 protein level in patients with LIHC compared to normal tissue: (C) normal liver tissue, (D) hepatocellular carcinoma tissue. ***p < 0.001

Correlation between RAC1 expression and LIHC clinicopathological parameters

To further assess the role of RAC1 in clinical traits, we examined RAC1 expression by analyzing the TCGA RNA-seq data in subgroups. The results indicate that RAC1 expression is significantly upregulated in higher histological grades, advanced pathological stages, higher AFP levels, and in samples with vascular invasion. These findings suggest that elevated RAC1 expression is closely associated with more aggressive clinical features. (Fig. 2).

Fig. 2 Differential expression levels of RAC1 in subgroups with clinical features. (A) Histological grades; (B) Pathologic stages; (C) AFP level; (D) Vascular invasion status. *p < 0.05; **p < 0.01; ***p < 0.001

Diagnostic value and prognostic potential of RAC1 in LIHC

We examined RAC1 protein levels in a tissue microarray consisting of 10 normal liver tissues and 10 LIHC tissues using immunohistochemistry (IHC). The results showed that RAC1 expression was significantly higher in LIHC tissues compared to normal tissues at the protein level (Fig. 3A and B). Consequently, we considered RAC1 as a potential diagnostic and prognostic marker for LIHC. We used the ROC curves to assess the performance of RAC1 in predicting result of LIHC. When predicting outcomes from normal or tumor tissue, the predictability of RAC1 (AUC = 0.915, 95% CI: 0.881–0.949) showed higher accuracy compared to AFP (AUC = 0.724, 95% CI: 0.671–0.776) (Fig. 3C). To determine the prognostic value of mRNA expression levels in LIHC, Kaplan-Meier curves were adopted to assess expression level in relation to patient survival and clinical follow-up period. Log-rank tests were performed to assess statistical significance. Our study revealed that high mRNA expression of RAC1 (HR = 1.973, 95% CI: 1.398–2.786, p < 0.001) was significantly associated with poor prognosis. (Fig. 3D)

Fig. 3 Diagnostic value and prognostic potential of RAC1 in LIHC (A) Expression and (B) scoring of RAC1 protein, as detected by IHC in 10 LIHC and 10 normal liver tissues (scale bar = 50 μm). (C) ROC curves and the predictability of RAC1; (D) Kaplan-Meier curve of overall survival and expression levels of RAC1; ROC, receiver operating characteristics; ***p < 0.001

High-level expression of RAC1 is an independent risk factor for OS of LIHC

Univariate Cox analysis showed that high RAC1 expression was significantly correlated with poor OS (HR = 1.977, 95% CI = 1.384–2.824, p < 0.001). Multivariate Cox analysis confirmed RAC1 gene expression was an independent risk factor for OS in patients with LIHC (HR = 1.847, 95% CI = 1.244–2.740, p = 0.002) (Table 1). Besides, tumor status (HR = 1.769, 95% CI = 1.182–2.647, p = 0.006) and pathological stages (HR = 2.139, 95% CI = 1.442–3.173, p < 0.001) were another independent risk factors in LIHC.

Table 1 Cox regression analyses of clinical characteristics related to LIHC overall survival

Characteristics	Total(N)	Univariate analysis		Multivariate analysis	
HR (95% CI)	P value	HR (95% CI)	P value	
Tumor status	354		< 0.001				
 Tumor free	202	Reference			Reference		
 With tumor	152	2.317 (1.590–3.376)	< 0.001		1.769 (1.182–2.647)	0.006	
Histologic grade	368		0.792				
 G1	55	Reference					
 G2	178	1.162 (0.686–1.969)	0.576				
 G3	123	1.185 (0.683–2.057)	0.545				
 G4	12	1.681 (0.621–4.549)	0.307				
Pathologic stage	349		< 0.001				
 Stage I & Stage II	259	Reference			Reference		
 Stage III & Stage IV	90	2.504 (1.727–3.631)	< 0.001		2.139 (1.442–3.173)	< 0.001	
Vascular invasion	317		0.169				
 No	208	Reference					
 Yes	109	1.344 (0.887–2.035)	0.163				
AFP(ng/ml)	279		0.773				
 <= 400	215	Reference					
 > 400	64	1.075 (0.658–1.759)	0.772				
RAC1	373		< 0.001				
 Low	187	Reference			Reference		
 High	186	1.977 (1.384–2.824)	< 0.001		1.847 (1.244–2.740)	0.002	
HR, hazard ratio; CI, confidence interval

Correlation between RAC1 expression and immune infiltration in LIHC

We have established a RAC1-associated immune-infiltrating landscape of tumor micro environment (TME) immune cells in LICH. The results showed that the expression of RAC1 was positively correlated with Th2, NK CD56 bright, macrophages and Tem cells, but negatively with Th17 cells (Fig. 4A) (Table S1). Kaplan-Meier plot curves were used to estimate the prognostic value of RAC1 expression levels in LIHC associated with infiltrating immune cells. Our analysis revealed that high mRNA expressions of RAC1 are significantly associated with poor prognosis of Th2-enriched patients (HR = 2.44, 95% CI: 1.42–4.19, p = 0.0008) (Fig. 4B and D) and macrophage-enriched patients (HR = 2.15, 95% CI: 1.33–3.49, p = 0.001) (Fig. 4C and E), but not the infiltrating immune cells decreased subgroups.

Fig. 4 Correlation between RAC1 expression and immune infiltration in LIHC. (A) Landscape of RAC1 correlation to infiltrating immune cells. *p < 0.05; **p < 0.01; ***p < 0.001. (B-C) Scatter diagram demonstrated the correlation between RAC1 genes expression and infiltrating immune cells. (B) Enrichment of Th2 cells; (C) Enrichment of macrophages; (D-E) Kaplan-Meier curve of overall survival for RAC1 gene expression associated with immune cell infiltration in LIHC. (D) subset enriched in Th2 cells; (E) subset enriched in macrophage cells

Knockdown of RAC1 inhibits the proliferation and migration of LIHC cells

To further investigate the biological role of RAC1 in LIHC development, we used siRNAs to knock down RAC1 in HepG2 and Huh7 cells. The efficiency of the knockdown was verified by qRT-PCR (Fig. 5A and B) and western blotting (Fig. 5C and D). Upon successful knockdown of RAC1, the migratory abilities of both LIHC cell lines were significantly inhibited (Fig. 5E and F). We also monitored the proliferation of LIHC cell lines after RAC1 knockdown using the CCK-8 assay. The results demonstrated that successful knockdown of RAC1 led to a significant reduction in the proliferation capacity of both HepG2 and Huh7 cells (Fig. 5H and I). Additionally, we investigated the effect of RAC1 knockdown on the proliferative capacity of LIHC cells in an animal model. The knockdown of RAC1 significantly slowed LIHC proliferation (Fig. 5I-K). These findings demonstrate that RAC1 is involved in the migration and proliferation of LIHC cells in vivo.

Fig. 5 Knockdown of RAC1 inhibits the proliferation and migration of LIHC cells. Interference efficiency of siRAC1 in HepG2 and Huh7 was assessed by qRT-PCR (A, B) and western blot (C, D) (n = 5). (E, F) Wound healing assays were performed in HepG2 and Huh7 cells with RAC1 knocking down (n = 5). (G, H) Proliferation rate of HepG2 and Huh7 cells with RAC1 knocking down (n = 3). (I, J) Tumor growth curves of HepG2 and Huh7 cells with RAC1 knocking down (n = 3). (K) Images of the tumor tissues collected after 12 days. ***p < 0.001

Relationships between RAC1 expression and immune markers

To further investigate the relationship between RAC1 and the infiltrating immune cells, we analyzed the correlations between several immune cell markers and Rac1 by coexpression heatmap. These markers have been used to characterize immune cells including Th2 cells and tumor-associated macrophages. The results showed that RAC1 was associated with Th2 cell markers GATA3 (r = 0.312, p = 8.14e-10), STAT6 (r = 0.227, p = 1.07e-05) and macrophage markers CCL2 (r = 0.250, p = 1.14e-06), IL10 (r = 0.243, p = 2.13e-06), VSIG4 (r = 0.292, p = 9.91e-09), MS4A4A (r = 0.266, p = 2.05e-07). In general, RAC1 was positively correlated with the tumor-infiltrating immune markers. We also analyzed the markers of exhausted T cells including PDCD1 (r = 0.314, p = 6.36e-10), CTLA4 (r = 0.307, p = 1.49e-09), TIGIT (r = 0.245, p = 1.75e-06), HAVCR2 (r = 0.401, p = 8.84e-16). (Fig. 6) (Table S2).

Fig. 6 Co-expression heatmap of RAC1 and infiltrating immune cell markers

Discussion

Rac1 is a key member of the Rho GTPase family. As a cytoskeletal regulatory protein, Rac1 primarily regulates cell adhesion and movement by promoting actin cytoskeleton remodeling(Machacek et al. 2009; Martin et al. 2016). It plays a crucial role in transducing migration signals to the cytoskeleton(Zegers and Friedl 2014; Navarro-Lérida et al. 2015; Swaminathan et al. 2021). Disruption of RAC1 interferes with cell adhesion and lamellipodia formation, affecting cytoskeletal dynamics and disrupting the dynamic interactions between cells and the extracellular matrix (ECM), thereby driving tumor cell invasion and migration(Arthur et al. 2002; Du et al. 2019; Liu et al. 2021). In head and neck squamous cell carcinoma (HNSCC), Rac1 participates in cell-matrix adhesion and promotes cancer cell migration through fibronectin, mediated by Ras-related protein 1 (Rap1)(Liu et al. 2020). Additionally, upregulation of Rac1 expression accelerates hepatocellular carcinoma metastasis by promoting lamellipodia formation in liver cancer cells via activation of downstream targets such as the Scar/Wave complex(Guo et al. 2019). Moreover, external mechanical stimuli regulate cytoskeletal remodeling and contraction in pancreatic cancer cells through Rac1 and other cytoskeletal remodeling factors, maintaining their motility(Kalli et al. 2022).

The role of RAC1 in the tumor immune microenvironment is complex and diverse, particularly in its regulation of immune cell functions and influence on tumor immune evasion(Carrizzo et al. 2014; Haga and Ridley 2016). RAC1 affects the activity and infiltration of tumor-associated immune cells such as plasma cells, lymphocytes, and macrophages, directly shaping the nature and strength of tumor immune responses(Porter et al. 2016; Lawson and Ridley 2017; Fionda et al. 2021). Research indicates that RAC1 can regulate the migration capacity of these immune cells within tumor tissues, impacting their distribution and functional roles(Maldonado and Dharmawardhane 2018; Zhu et al. 2021). This not only alters the composition and behavior of immune cells but also their ability to detect and target tumor cells(Wang et al. 2013).Furthermore, RAC1 is pivotal in mediating interactions between immune cells and tumor cells(Bosco et al. 2008). For instance, it modulates the phagocytic activity of macrophages, influencing their efficacy in killing tumor cells(Song et al. 2024; Bailly et al. 2024). Additionally, RAC1 plays a critical role in regulating the expression and function of immune checkpoint molecules, thereby affecting T cell activation and the ability of tumor cells to evade immune detection(Mishra et al. 2023; Tao et al. 2024). Of paramount importance is the finding that aberrant activation of the RAC1 signaling pathway is closely linked to the development and progression of various types of cancers, including breast cancer, melanoma, and prostate cancer(Sauzeau et al. 2022a, b; Bailly et al. 2022; Ma et al. 2023). Therefore, understanding and targeting RAC1 in the tumor immune microenvironment could provide a solid foundation for developing new immune-based therapies(Arnst et al. 2017).

In our study, we observed that RAC1 gene expression in LIHC was significantly higher compared to normal tissues. This upregulated RAC1 gene expression was closely associated with various pathological parameters, including histological grade, clinical stage, AFP level, and vascular invasion status. Importantly, multivariate Cox analysis demonstrated that RAC1 expression serves as an independent factor influencing overall survival in LIHC patients. ROC analysis confirmed the potential prognostic value of RAC1 in LIHC, and Kaplan-Meier survival analysis revealed that patients with high RAC1 gene expression had significantly shorter overall survival (p < 0.001). Concurrently, we constructed RAC1 knockdown LIHC cell lines to investigate its impact on cell proliferation and migration. Knockdown of RAC1 significantly inhibited LIHC migration and also suppressed the proliferation of LIHC in subcutaneous tumor models. Therefore, high RAC1 gene expression severely worsens patient prognosis by promoting LIHC migration and proliferation.

To further investigate the relationship between RAC1 and tumor immune infiltration, we established a RAC1-associated tumor immune microenvironment profile. We found that RAC1 was significantly differentially expressed in various tumor-infiltrating immune cells, particularly in Th2 cells and tumor-associated macrophages. Incorporating RAC1 expression in immune cells into our prognostic assessment, we found that high RAC1 expression in Th2 cells and macrophages was associated with reduced survival in LIHC patients. This indicates that RAC1 influences the prognosis of LIHC patients by modulating the tumor immune microenvironment.

In summary, this study demonstrates that RAC1 gene expression can serve not only as a diagnostic factor for the development of LIHC but also as an independent prognostic marker. The correlation analysis of RAC1 with various clinicopathological parameters further substantiates this hypothesis. High RAC1 gene expression promotes LIHC proliferation and migration and is significantly associated with poor prognosis. Furthermore, our research indicates that RAC1 gene expression exhibits diverse associations with tumor-infiltrating immune cells, such as Th2 cells, tumor-associated macrophages, and even exhausted T cells, suggesting its potential as a target for immune therapy in LIHC. However, the underlying signaling pathways require further investigation.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Material 1

Author contributions

Yuan Li and Aidong Gu are equal for the contribution for this work. Conceptualization, Yuan Li and Aidong Gu; methodology, Yuan Li; software, Aidong Gu; validation, Aidong Gu and Yuan Li; resources, Lili Yang; data curation, Yuan Li; writing—original draft preparation, Aidong Gu and Yuan Li; writing—review and editing, Qingbo Wang; supervision, Qingbo Wang; project administration, Qingbo Wang. All authors have read and agreed to the published version of the manuscript.

Data availability

Data is provided within the manuscript or supplementary information files.

Declarations

Ethical approval

This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Nanjing University of Chinese Medicine.

Competing interests

The authors declare no competing interests.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Yuan Li and Aidong Gu contributed equally to this work.
==== Refs
References

Al-Koussa H Atat OE Jaafar L Tashjian H El-Sibai M The role of rho GTPases in Motility and Invasion of Glioblastoma Cells Anal Cell Pathol 2020 2020 1 9 10.1155/2020/9274016
Al-Koussa H, Atat OE, Jaafar L, Tashjian H, El-Sibai M (2020) The role of rho GTPases in Motility and Invasion of Glioblastoma Cells. Anal Cell Pathol 2020:1–9. 10.1155/2020/927401610.1155/2020/9274016
Alvarez DE Agaisse H A role for the small GTPase Rac1 in vaccinia actin-based motility Small GTPases 2014 10.4161/sgtp.29038 25483216
Alvarez DE, Agaisse H (2014) A role for the small GTPase Rac1 in vaccinia actin-based motility. Small GTPases. 10.4161/sgtp.2903825483216 10.4161/sgtp.29038
Arnst JL Hein AL Taylor MA Palermo NY Contreras JI Sonawane YA Wahl AO Ouellette MM Natarajan A Yan Y Discovery and characterization of small molecule Rac1 inhibitors Oncotarget 2017 8 21 34586 34600 10.18632/oncotarget.16656 28410221
Arnst JL, Hein AL, Taylor MA, Palermo NY, Contreras JI, Sonawane YA, Wahl AO, Ouellette MM, Natarajan A, Yan Y (2017) Discovery and characterization of small molecule Rac1 inhibitors. Oncotarget 8(21):34586–34600. 10.18632/oncotarget.1665628410221 10.18632/oncotarget.16656
Arthur WT Noren NK Burridge K Regulation of rho family GTPases by cell-cell and cell-matrix adhesion Biol Res 2002 35 2 239 246 10.4067/s0716-97602002000200016 12415742
Arthur WT, Noren NK, Burridge K (2002) Regulation of rho family GTPases by cell-cell and cell-matrix adhesion. Biol Res 35(2):239–246. 10.4067/s0716-9760200200020001612415742 10.4067/s0716-97602002000200016
Bailly C Beignet J Loirand G Sauzeau V Rac1 as a therapeutic anticancer target: promises and limitations Biochem Pharmacol 2022 203 115180 10.1016/j.bcp.2022.115180 35853497
Bailly C, Beignet J, Loirand G, Sauzeau V (2022) Rac1 as a therapeutic anticancer target: promises and limitations. Biochem Pharmacol 203:115180. 10.1016/j.bcp.2022.11518035853497 10.1016/j.bcp.2022.115180
Bailly C Degand C Laine W Sauzeau V Kluza J Implication of Rac1 GTPase in molecular and cellular mitochondrial functions Life Sci 2024 342 122510 10.1016/j.lfs.2024.122510 38387701
Bailly C, Degand C, Laine W, Sauzeau V, Kluza J (2024) Implication of Rac1 GTPase in molecular and cellular mitochondrial functions. Life Sci 342:122510. 10.1016/j.lfs.2024.12251038387701 10.1016/j.lfs.2024.122510
Bosco EE Mulloy JC Zheng Y Rac1 GTPase: a rac of all trades Cell Mol Life Sci 2008 66 3 370 10.1007/s00018-008-8552-x
Bosco EE, Mulloy JC, Zheng Y (2008) Rac1 GTPase: a rac of all trades. Cell Mol Life Sci 66(3):370. 10.1007/s00018-008-8552-x10.1007/s00018-008-8552-x
Cannon AC Uribe-Alvarez C Chernoff J RAC1 as a therapeutic target in malignant melanoma Trends Cancer 2020 6 6 478 488 10.1016/j.trecan.2020.02.021 32460002
Cannon AC, Uribe-Alvarez C, Chernoff J (2020) RAC1 as a therapeutic target in malignant melanoma. Trends Cancer 6(6):478–488. 10.1016/j.trecan.2020.02.02132460002 10.1016/j.trecan.2020.02.021
Carrizzo A Forte M Lembo M Formisano L Puca AA Vecchione C Rac-1 as a new therapeutic target in cerebro- and cardio-vascular diseases Curr Drug Targets 2014 15 13 1231 1246 10.2174/1389450115666141027110156 25345393
Carrizzo A, Forte M, Lembo M, Formisano L, Puca AA, Vecchione C (2014) Rac-1 as a new therapeutic target in cerebro- and cardio-vascular diseases. Curr Drug Targets 15(13):1231–1246. 10.2174/138945011566614102711015625345393 10.2174/1389450115666141027110156
De P Aske JC Dey N RAC1 takes the lead in solid tumors Cells 2019 8 5 382 10.3390/cells8050382 31027363
De P, Aske JC, Dey N (2019) RAC1 takes the lead in solid tumors. Cells 8(5):382. 10.3390/cells805038231027363 10.3390/cells8050382
Du G-S Qiu Y Wang W-S Peng K Zhang Z-C Li X-S Xiao W-D Yang H Knockdown on aPKC-ι inhibits epithelial-mesenchymal transition, migration and invasion of colorectal cancer cells through Rac1-JNK pathway Exp Mol Pathol 2019 107 57 67 10.1016/j.yexmp.2018.11.007 30465755
Du G-S, Qiu Y, Wang W-S, Peng K, Zhang Z-C, Li X-S, Xiao W-D, Yang H (2019) Knockdown on aPKC-ι inhibits epithelial-mesenchymal transition, migration and invasion of colorectal cancer cells through Rac1-JNK pathway. Exp Mol Pathol 107:57–67. 10.1016/j.yexmp.2018.11.00730465755 10.1016/j.yexmp.2018.11.007
Fionda C Stabile H Molfetta R Kosta A Peruzzi G Ruggeri S Zingoni A Capuano C Soriani A Paolini R Gismondi A Cippitelli M Santoni A Cereblon regulates NK cell cytotoxicity and migration via Rac1 activation Eur J Immunol 2021 51 11 2607 2617 10.1002/eji.202149269 34392531
Fionda C, Stabile H, Molfetta R, Kosta A, Peruzzi G, Ruggeri S, Zingoni A, Capuano C, Soriani A, Paolini R, Gismondi A, Cippitelli M, Santoni A (2021) Cereblon regulates NK cell cytotoxicity and migration via Rac1 activation. Eur J Immunol 51(11):2607–2617. 10.1002/eji.20214926934392531 10.1002/eji.202149269
Guo Y Zhu J Wang X Li R Jiang K Chen S Fan J Xue L Hao D Orai1 promotes Osteosarcoma Metastasis by activating the Ras-Rac1-WAVE2 signaling pathway Med Sci Monit Int Med J Exp Clin Res 2019 25 9227 9236 10.12659/MSM.919594
Guo Y, Zhu J, Wang X, Li R, Jiang K, Chen S, Fan J, Xue L, Hao D (2019) Orai1 promotes Osteosarcoma Metastasis by activating the Ras-Rac1-WAVE2 signaling pathway. Med Sci Monit Int Med J Exp Clin Res 25:9227–9236. 10.12659/MSM.91959410.12659/MSM.919594
Haga RB Ridley AJ Rho GTPases: regulation and roles in cancer cell biology Small GTPases 2016 7 4 207 221 10.1080/21541248.2016.1232583 27628050
Haga RB, Ridley AJ (2016) Rho GTPases: regulation and roles in cancer cell biology. Small GTPases 7(4):207–221. 10.1080/21541248.2016.123258327628050 10.1080/21541248.2016.1232583
Hudson LG Gillette JM Kang H Rivera MR Wandinger-Ness A Ovarian Tumor Microenvironment Signaling: convergence on the Rac1 GTPase Cancers 2018 10 10 358 10.3390/cancers10100358 30261690
Hudson LG, Gillette JM, Kang H, Rivera MR, Wandinger-Ness A (2018) Ovarian Tumor Microenvironment Signaling: convergence on the Rac1 GTPase. Cancers 10(10):358. 10.3390/cancers1010035830261690 10.3390/cancers10100358
Jin C, Chen H, Xie L, Zhou Y, Liu L, Wu J (2024) GPCRs involved in metabolic diseases: pharmacotherapeutic development updates. Acta Pharmacol Sin 1–16. 10.1038/s41401-023-01215-2
Kalli M Li R Mills GB Stylianopoulos T Zervantonakis IK Mechanical stress signaling in pancreatic Cancer cells triggers p38 MAPK- and JNK-Dependent cytoskeleton remodeling and promotes Cell Migration via Rac1/cdc42/Myosin II Mol Cancer Res 2022 20 3 485 497 10.1158/1541-7786.MCR-21-0266 34782370
Kalli M, Li R, Mills GB, Stylianopoulos T, Zervantonakis IK (2022) Mechanical stress signaling in pancreatic Cancer cells triggers p38 MAPK- and JNK-Dependent cytoskeleton remodeling and promotes Cell Migration via Rac1/cdc42/Myosin II. Mol Cancer Res 20(3):485–497. 10.1158/1541-7786.MCR-21-026634782370 10.1158/1541-7786.MCR-21-0266
Kotelevets L Chastre E Rac1 signaling: from intestinal homeostasis to Colorectal Cancer Metastasis Cancers 2020 12 3 665 10.3390/cancers12030665 32178475
Kotelevets L, Chastre E (2020) Rac1 signaling: from intestinal homeostasis to Colorectal Cancer Metastasis. Cancers 12(3):665. 10.3390/cancers1203066532178475 10.3390/cancers12030665
Lawson CD Ridley AJ Rho GTPase signaling complexes in cell migration and invasion J Cell Biol 2017 217 2 447 457 10.1083/jcb.201612069 29233866
Lawson CD, Ridley AJ (2017) Rho GTPase signaling complexes in cell migration and invasion. J Cell Biol 217(2):447–457. 10.1083/jcb.20161206929233866 10.1083/jcb.201612069
Liu M Banerjee R Rossa C D’Silva NJ RAP1-RAC1 signaling has an important role in Adhesion and Migration in HNSCC J Dent Res 2020 99 8 959 968 10.1177/0022034520917058 32401565
Liu M, Banerjee R, Rossa C, D’Silva NJ (2020) RAP1-RAC1 signaling has an important role in Adhesion and Migration in HNSCC. J Dent Res 99(8):959–968. 10.1177/002203452091705832401565 10.1177/0022034520917058
Liu S Gu L Wu N Song J Yan J Yang S Feng Y Wang Z Wang L Zhang Y Jin Y Overexpression of DTL enhances cell motility and promotes tumor metastasis in cervical adenocarcinoma by inducing RAC1-JNK-FOXO1 axis Cell Death Dis 2021 12 10 929 10.1038/s41419-021-04179-5 34635635
Liu S, Gu L, Wu N, Song J, Yan J, Yang S, Feng Y, Wang Z, Wang L, Zhang Y, Jin Y (2021) Overexpression of DTL enhances cell motility and promotes tumor metastasis in cervical adenocarcinoma by inducing RAC1-JNK-FOXO1 axis. Cell Death Dis 12(10):929. 10.1038/s41419-021-04179-534635635 10.1038/s41419-021-04179-5
Ma N Xu E Luo Q Song G Rac1: a Regulator of Cell Migration and a potential target for Cancer Therapy Mol Basel Switz 2023 28 7 2976 10.3390/molecules28072976
Ma N, Xu E, Luo Q, Song G (2023) Rac1: a Regulator of Cell Migration and a potential target for Cancer Therapy. Mol Basel Switz 28(7):2976. 10.3390/molecules2807297610.3390/molecules28072976
Machacek M Hodgson L Welch C Elliott H Pertz O Nalbant P Abell A Johnson GL Hahn KM Danuser G Coordination of rho GTPase activities during cell protrusion Nature 2009 461 7260 99 103 10.1038/nature08242 19693013
Machacek M, Hodgson L, Welch C, Elliott H, Pertz O, Nalbant P, Abell A, Johnson GL, Hahn KM, Danuser G (2009) Coordination of rho GTPase activities during cell protrusion. Nature 461(7260):99–103. 10.1038/nature0824219693013 10.1038/nature08242
Maldonado M del Dharmawardhane M Targeting Rac and Cdc42 GTPases in Cancer Cancer Res 2018 78 12 3101 3111 10.1158/0008-5472.CAN-18-0619 29858187
Maldonado M, del Dharmawardhane M S (2018) Targeting Rac and Cdc42 GTPases in Cancer. Cancer Res 78(12):3101–3111. 10.1158/0008-5472.CAN-18-061929858187 10.1158/0008-5472.CAN-18-0619
Martin K Reimann A Fritz RD Ryu H Jeon NL Pertz O Spatio-temporal co-ordination of RhoA, Rac1 and Cdc42 activation during prototypical edge protrusion and retraction dynamics Sci Rep 2016 6 21901 10.1038/srep21901 26912264
Martin K, Reimann A, Fritz RD, Ryu H, Jeon NL, Pertz O (2016) Spatio-temporal co-ordination of RhoA, Rac1 and Cdc42 activation during prototypical edge protrusion and retraction dynamics. Sci Rep 6:21901. 10.1038/srep2190126912264 10.1038/srep21901
Mishra AK Rodriguez M Torres AY Smith M Rodriguez A Bond A Morrissey MA Montell DJ Hyperactive rac stimulates cannibalism of living target cells and enhances CAR-M-mediated cancer cell killing Proc Natl Acad Sci U S A 2023 120 52 e2310221120 10.1073/pnas.2310221120 38109551
Mishra AK, Rodriguez M, Torres AY, Smith M, Rodriguez A, Bond A, Morrissey MA, Montell DJ (2023) Hyperactive rac stimulates cannibalism of living target cells and enhances CAR-M-mediated cancer cell killing. Proc Natl Acad Sci U S A 120(52):e2310221120. 10.1073/pnas.231022112038109551 10.1073/pnas.2310221120
Navarro-Lérida I Pellinen T Sanchez SA Guadamillas MC Wang Y Mirtti T Calvo E Del Pozo MA Rac1 nucleocytoplasmic shuttling drives nuclear shape changes and tumor invasion Dev Cell 2015 32 3 318 334 10.1016/j.devcel.2014.12.019 25640224
Navarro-Lérida I, Pellinen T, Sanchez SA, Guadamillas MC, Wang Y, Mirtti T, Calvo E, Del Pozo MA (2015) Rac1 nucleocytoplasmic shuttling drives nuclear shape changes and tumor invasion. Dev Cell 32(3):318–334. 10.1016/j.devcel.2014.12.01925640224 10.1016/j.devcel.2014.12.019
Porter AP Papaioannou A Malliri A Deregulation of rho GTPases in cancer Small GTPases 2016 7 3 123 138 10.1080/21541248.2016.1173767 27104658
Porter AP, Papaioannou A, Malliri A (2016) Deregulation of rho GTPases in cancer. Small GTPases 7(3):123–138. 10.1080/21541248.2016.117376727104658 10.1080/21541248.2016.1173767
Sanz-Moreno V Gadea G Ahn J Paterson H Marra P Pinner S Sahai E Marshall CJ Rac Activation and Inactivation Control Plasticity of Tumor Cell Movement Cell 2008 135 3 510 523 10.1016/j.cell.2008.09.043 18984162
Sanz-Moreno V, Gadea G, Ahn J, Paterson H, Marra P, Pinner S, Sahai E, Marshall CJ (2008) Rac Activation and Inactivation Control Plasticity of Tumor Cell Movement. Cell 135(3):510–523. 10.1016/j.cell.2008.09.04318984162 10.1016/j.cell.2008.09.043
Sauzeau V Beignet J Bailly C Rac1 as a target to treat dysfunctions and Cancer of the bladder Biomedicines 2022 10 6 1357 10.3390/biomedicines10061357 35740379
Sauzeau V, Beignet J, Bailly C (2022a) Rac1 as a target to treat dysfunctions and Cancer of the bladder. Biomedicines 10(6):1357. 10.3390/biomedicines1006135735740379 10.3390/biomedicines10061357
Sauzeau V Beignet J Vergoten G Bailly C Overexpressed or hyperactivated Rac1 as a target to treat hepatocellular carcinoma Pharmacol Res 2022 179 106220 10.1016/j.phrs.2022.106220 35405309
Sauzeau V, Beignet J, Vergoten G, Bailly C (2022b) Overexpressed or hyperactivated Rac1 as a target to treat hepatocellular carcinoma. Pharmacol Res 179:106220. 10.1016/j.phrs.2022.10622035405309 10.1016/j.phrs.2022.106220
Shi X Chen W Yin Y Cao H Wang X Jiang W Li Q Li X Yu Y Wang X RAC1high NK cell-based immunotherapy in hepatocellular carcinoma via STAT3-NKG2D axis Cancer Lett 2024 592 216909 10.1016/j.canlet.2024.216909 38679407
Shi X, Chen W, Yin Y, Cao H, Wang X, Jiang W, Li Q, Li X, Yu Y, Wang X (2024) RAC1high NK cell-based immunotherapy in hepatocellular carcinoma via STAT3-NKG2D axis. Cancer Lett 592:216909. 10.1016/j.canlet.2024.21690938679407 10.1016/j.canlet.2024.216909
Song Y Liu Y Guo F Zhao L Qin G Single-cell RNA sequencing reveals RAC1 involvement in Macrophages Efferocytosis in Diabetic kidney disease Inflammation 2024 47 2 753 770 10.1007/s10753-023-01942-y 38064011
Song Y, Liu Y, Guo F, Zhao L, Qin G (2024) Single-cell RNA sequencing reveals RAC1 involvement in Macrophages Efferocytosis in Diabetic kidney disease. Inflammation 47(2):753–770. 10.1007/s10753-023-01942-y38064011 10.1007/s10753-023-01942-y
Swaminathan K Campbell A Papalazarou V Jaber-Hijazi F Nixon C McGhee E Strathdee D Sansom OJ Machesky LM The RAC1 target NCKAP1 plays a crucial role in the progression of Braf;Pten-Driven Melanoma in mice J Invest Dermatol 2021 141 3 628 637e15 10.1016/j.jid.2020.06.029 32777214
Swaminathan K, Campbell A, Papalazarou V, Jaber-Hijazi F, Nixon C, McGhee E, Strathdee D, Sansom OJ, Machesky LM (2021) The RAC1 target NCKAP1 plays a crucial role in the progression of Braf;Pten-Driven Melanoma in mice. J Invest Dermatol 141(3):628–637e15. 10.1016/j.jid.2020.06.02932777214 10.1016/j.jid.2020.06.029
Tao L Xu X Fang Z Christopoulos P Cortinovis D Lu Y RAC1 as a potential pan-cancer diagnostic, prognostic, and immunological biomarker Transl Cancer Res 2024 13 3 1533 1553 10.21037/tcr-23-2016 38617518
Tao L, Xu X, Fang Z, Christopoulos P, Cortinovis D, Lu Y (2024) RAC1 as a potential pan-cancer diagnostic, prognostic, and immunological biomarker. Transl Cancer Res 13(3):1533–1553. 10.21037/tcr-23-201638617518 10.21037/tcr-23-2016
Tátrai E Ranđelović I Surguta SE Tóvári J Role of Hypoxia and Rac1 inhibition in the Metastatic Cascade Cancers 2024 16 10 1872 10.3390/cancers16101872 38791951
Tátrai E, Ranđelović I, Surguta SE, Tóvári J (2024) Role of Hypoxia and Rac1 inhibition in the Metastatic Cascade. Cancers 16(10):1872. 10.3390/cancers1610187238791951 10.3390/cancers16101872
Wang J-Y Yu P Chen S Xing H Chen Y Wang M Tang K Tian Z Rao Q Wang J Activation of Rac1 GTPase promotes leukemia cell chemotherapy resistance, quiescence and niche interaction Mol Oncol 2013 7 5 907 916 10.1016/j.molonc.2013.05.001 23726395
Wang J-Y, Yu P, Chen S, Xing H, Chen Y, Wang M, Tang K, Tian Z, Rao Q, Wang J (2013) Activation of Rac1 GTPase promotes leukemia cell chemotherapy resistance, quiescence and niche interaction. Mol Oncol 7(5):907–916. 10.1016/j.molonc.2013.05.00123726395 10.1016/j.molonc.2013.05.001
Yamauchi A Marchal CC Molitoris J Pech N Knaus U Towe J Atkinson SJ Dinauer MC Rac GTPase isoform-specific regulation of NADPH oxidase and Chemotaxis in murine neutrophils in vivo: ROLE OF THE C-TERMINAL POLYBASIC DOMAIN * J Biol Chem 2005 280 2 953 964 10.1074/jbc.M408820200 15504745
Yamauchi A, Marchal CC, Molitoris J, Pech N, Knaus U, Towe J, Atkinson SJ, Dinauer MC (2005) Rac GTPase isoform-specific regulation of NADPH oxidase and Chemotaxis in murine neutrophils in vivo: ROLE OF THE C-TERMINAL POLYBASIC DOMAIN *. J Biol Chem 280(2):953–964. 10.1074/jbc.M40882020015504745 10.1074/jbc.M408820200
Zegers MM Friedl P Rho GTPases in collective cell migration Small GTPases 2014 5 e28997 10.4161/sgtp.28997 25054920
Zegers MM, Friedl P (2014) Rho GTPases in collective cell migration. Small GTPases 5:e28997. 10.4161/sgtp.2899725054920 10.4161/sgtp.28997
Zhou H-C Liu C-X Pan W-D Shang L-R Zheng J-L Huang B-Y Chen J-Y Zheng L Fang J-H Zhuang S-M Dual and opposing roles of the androgen receptor in VETC-dependent and invasion-dependent metastasis of hepatocellular carcinoma J Hepatol 2021 75 4 900 911 10.1016/j.jhep.2021.04.053 34004215
Zhou H-C, Liu C-X, Pan W-D, Shang L-R, Zheng J-L, Huang B-Y, Chen J-Y, Zheng L, Fang J-H, Zhuang S-M (2021) Dual and opposing roles of the androgen receptor in VETC-dependent and invasion-dependent metastasis of hepatocellular carcinoma. J Hepatol 75(4):900–911. 10.1016/j.jhep.2021.04.05334004215 10.1016/j.jhep.2021.04.053
Zhu Y Xie J Shi J Rac1/ROCK-driven membrane dynamics promote natural killer cell cytotoxicity via granzyme-induced necroptosis BMC Biol 2021 19 1 140 10.1186/s12915-021-01068-3 34325694
Zhu Y, Xie J, Shi J (2021) Rac1/ROCK-driven membrane dynamics promote natural killer cell cytotoxicity via granzyme-induced necroptosis. BMC Biol 19(1):140. 10.1186/s12915-021-01068-334325694 10.1186/s12915-021-01068-3
